Summary of Study ST002229
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001419. The data can be accessed directly via it's Project DOI: 10.21228/M89D8V This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
Study ID | ST002229 |
Study Title | Estrogen receptor α deficiency in cardiac myocytes reprograms heart-derived extracellular vesicle proteome and induces obesity in female mice (Part 1) |
Study Summary | Dysregulation of ERα has been linked with increased metabolic and cardiovascular disease risk. Uncovering the impact of ERα deficiency in specific tissues has implications for understanding the role of ERα in normal physiology and disease, the increased disease risk in postmenopausal women, and the design of tissue-specific ERα-based therapies for a range of pathologies including cardiac disease and cancer. Cardiac myocyte-specific ER knockout mice (ERαHKO) were generated to assess the role of ERα in the heart. Female ERαHKO mice displayed a modest cardiac phenotype, but unexpectedly, the most striking phenotype was obesity in female ERαHKO but not male ERαHKO mice. In female ERαHKO mice we identified cardiac dysfunction, mild glucose and insulin intolerance, and reduced ERα gene expression in skeletal muscle and white adipose tissue (WAT). Gene expression, protein, lipidomic and metabolomic analyses showed evidence of contractile and/or metabolic dysregulation in heart, skeletal muscle and WAT. We also show that extracellular vesicles (EVs) collected from the perfusate of isolated hearts from female ERαHKO mice have a distinct proteome, and these EVs have the capacity to reprogram the proteome of a skeletal muscle cell including proteins linked with ERα, fatty acid regulation, lipid metabolism and mitochondrial function. This study uncovers a cardiac-initiated and sex-specific cardiometabolic phenotype that is regulated by ERα. |
Institute | Baker Heart and Diabetes Institute |
Last Name | Tham |
First Name | Yow Keat |
Address | 75 Commercial Rd, Melbourne, Victoria, 3004, Australia |
yowkeat.tham@baker.edu.au | |
Phone | +65385321266 |
Submit Date | 2022-05-18 |
Num Groups | 4 |
Total Subjects | 25 |
Num Males | 10 |
Num Females | 15 |
Raw Data Available | Yes |
Raw Data File Type(s) | d |
Analysis Type Detail | LC-MS |
Release Date | 2023-01-02 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
Project ID: | PR001419 |
Project DOI: | doi: 10.21228/M89D8V |
Project Title: | Estrogen receptor α deficiency in cardiac myocytes reprograms heart-derived extracellular vesicle proteome and induces obesity in female mice |
Project Summary: | Tissues (ventricles, skeletal muscles-soleus, subcutaneous fat) from male and female ERalpha cardiac-specific knockout and floxed control aged mice (54-59 weeks old, male FC n=5, male KO n=5, female FC n=8, female KO n=7 ) were subjected to metabolomic profiling. |
Institute: | Baker Heart and Diabetes Institute |
Department: | Discovery and Preclinical Science |
Laboratory: | Cardiac Hypertrophy |
Last Name: | Tham |
First Name: | Yow Keat |
Address: | 75 Commercial Rd, Melbourne, Victoria, 3004, Australia |
Email: | yowkeat.tham@baker.edu.au |
Phone: | 0385321266 |
Publications: | https://www.nature.com/articles/s44161-023-00223-z |
Subject:
Subject ID: | SU002315 |
Subject Type: | Mammal |
Subject Species: | Mus musculus |
Taxonomy ID: | 10090 |
Genotype Strain: | C57BL6 and FVB mixed strain |
Age Or Age Range: | 54-59 weeks old |
Gender: | Male and female |
Animal Feed: | Specialty Feeds Irradiated Rat and Mouse Standard Chow Diet |
Factors:
Subject type: Mammal; Subject species: Mus musculus (Factor headings shown in green)
mb_sample_id | local_sample_id | Sex | Genotype | Tissue |
---|---|---|---|---|
SA212452 | 37905_epi | Female | ERalpha-knockout | EPlasmaididymal fat |
SA212454 | 37906_epi | Female | ERalpha-knockout | EPlasmaididymal fat |
SA212455 | 37910_epi | Female | ERalpha-knockout | EPlasmaididymal fat |
SA212456 | 37915_epi | Female | ERalpha-knockout | EPlasmaididymal fat |
SA212457 | 37899_epi | Female | ERalpha-knockout | EPlasmaididymal fat |
SA212463 | 37914_epi | Female | ERalpha-knockout | EPlasmaididymal fat |
SA212430 | 37899_Liv | Female | ERalpha-knockout | Liver |
SA212433 | 37906_Liv | Female | ERalpha-knockout | Liver |
SA212435 | 37917_Liv | Female | ERalpha-knockout | Liver |
SA212438 | 37910_Liv | Female | ERalpha-knockout | Liver |
SA212451 | 37905_Liv | Female | ERalpha-knockout | Liver |
SA212458 | 37915_Liv | Female | ERalpha-knockout | Liver |
SA212462 | 37914_Liv | Female | ERalpha-knockout | Liver |
SA212440 | 37899 _P | Female | ERalpha-knockout | Plasma |
SA212441 | 37914 _P | Female | ERalpha-knockout | Plasma |
SA212442 | 37915 _P | Female | ERalpha-knockout | Plasma |
SA212445 | 37910 _P | Female | ERalpha-knockout | Plasma |
SA212446 | 37917 _P | Female | ERalpha-knockout | Plasma |
SA212448 | 37905 _P | Female | ERalpha-knockout | Plasma |
SA212449 | 37906 _P | Female | ERalpha-knockout | Plasma |
SA212431 | 37915_Sk | Female | ERalpha-knockout | Skeletal muscle |
SA212432 | 37910_Sk | Female | ERalpha-knockout | Skeletal muscle |
SA212434 | 37914_Sk | Female | ERalpha-knockout | Skeletal muscle |
SA212439 | 37917_Sk | Female | ERalpha-knockout | Skeletal muscle |
SA212443 | 37905_Sk | Female | ERalpha-knockout | Skeletal muscle |
SA212444 | 37899_Sk | Female | ERalpha-knockout | Skeletal muscle |
SA212450 | 37906_Sk | Female | ERalpha-knockout | Skeletal muscle |
SA212436 | 37914_H | Female | ERalpha-knockout | Ventricles |
SA212437 | 37915_H | Female | ERalpha-knockout | Ventricles |
SA212447 | 37910_H | Female | ERalpha-knockout | Ventricles |
SA212453 | 37917_H | Female | ERalpha-knockout | Ventricles |
SA212459 | 37905_H | Female | ERalpha-knockout | Ventricles |
SA212460 | 37906_H | Female | ERalpha-knockout | Ventricles |
SA212461 | 37899_H | Female | ERalpha-knockout | Ventricles |
SA212464 | 37913_epi | Female | Floxed Control | EPlasmaididymal fat |
SA212469 | 37912_epi | Female | Floxed Control | EPlasmaididymal fat |
SA212472 | 37893_epi | Female | Floxed Control | EPlasmaididymal fat |
SA212481 | 37896_epi | Female | Floxed Control | EPlasmaididymal fat |
SA212482 | 37909_epi | Female | Floxed Control | EPlasmaididymal fat |
SA212483 | 37891_epi | Female | Floxed Control | EPlasmaididymal fat |
SA212484 | 37890_epi | Female | Floxed Control | EPlasmaididymal fat |
SA212486 | 37916_epi | Female | Floxed Control | EPlasmaididymal fat |
SA212473 | 37909_Liv | Female | Floxed Control | Liver |
SA212474 | 37896_Liv | Female | Floxed Control | Liver |
SA212475 | 37916_Liv | Female | Floxed Control | Liver |
SA212476 | 37912_Liv | Female | Floxed Control | Liver |
SA212478 | 37913_Liv | Female | Floxed Control | Liver |
SA212479 | 37893_Liv | Female | Floxed Control | Liver |
SA212480 | 37891_Liv | Female | Floxed Control | Liver |
SA212485 | 37890_Liv | Female | Floxed Control | Liver |
SA212489 | 37896 _P | Female | Floxed Control | Plasma |
SA212490 | 37916 _P | Female | Floxed Control | Plasma |
SA212491 | 37912 _P | Female | Floxed Control | Plasma |
SA212494 | 37890 _P | Female | Floxed Control | Plasma |
SA212495 | 37891 _P | Female | Floxed Control | Plasma |
SA212496 | 37893 _P | Female | Floxed Control | Plasma |
SA212497 | 37913 _P | Female | Floxed Control | Plasma |
SA212498 | 37909 _P | Female | Floxed Control | Plasma |
SA212465 | 37916_Sk | Female | Floxed Control | Skeletal muscle |
SA212466 | 37896_Sk | Female | Floxed Control | Skeletal muscle |
SA212467 | 37891_Sk | Female | Floxed Control | Skeletal muscle |
SA212468 | 37909_Sk | Female | Floxed Control | Skeletal muscle |
SA212470 | 37912_Sk | Female | Floxed Control | Skeletal muscle |
SA212471 | 37913_Sk | Female | Floxed Control | Skeletal muscle |
SA212477 | 37890_Sk | Female | Floxed Control | Skeletal muscle |
SA212487 | 37893_Sk | Female | Floxed Control | Skeletal muscle |
SA212488 | 37916_H | Female | Floxed Control | Ventricles |
SA212492 | 37912_H | Female | Floxed Control | Ventricles |
SA212493 | 37913_H | Female | Floxed Control | Ventricles |
SA212499 | 37909_H | Female | Floxed Control | Ventricles |
SA212500 | 37891_H | Female | Floxed Control | Ventricles |
SA212501 | 37890_H | Female | Floxed Control | Ventricles |
SA212502 | 37896_H | Female | Floxed Control | Ventricles |
SA212503 | 37893_H | Female | Floxed Control | Ventricles |
SA212511 | 37901_epi | Male | ERalpha-knockout | EPlasmaididymal fat |
SA212512 | 37908_epi | Male | ERalpha-knockout | EPlasmaididymal fat |
SA212514 | 37904_epi | Male | ERalpha-knockout | EPlasmaididymal fat |
SA212515 | 37902_epi | Male | ERalpha-knockout | EPlasmaididymal fat |
SA212516 | 37898_epi | Male | ERalpha-knockout | EPlasmaididymal fat |
SA212520 | 37902_Liv | Male | ERalpha-knockout | Liver |
SA212524 | 37898_Liv | Male | ERalpha-knockout | Liver |
SA212526 | 37901_Liv | Male | ERalpha-knockout | Liver |
SA212527 | 37908_Liv | Male | ERalpha-knockout | Liver |
SA212528 | 37904_Liv | Male | ERalpha-knockout | Liver |
SA212505 | 37898 _P | Male | ERalpha-knockout | Plasma |
SA212510 | 37902 _P | Male | ERalpha-knockout | Plasma |
SA212513 | 37904 _P | Male | ERalpha-knockout | Plasma |
SA212518 | 37901 _P | Male | ERalpha-knockout | Plasma |
SA212523 | 37908 _P | Male | ERalpha-knockout | Plasma |
SA212504 | 37908_Sk | Male | ERalpha-knockout | Skeletal muscle |
SA212519 | 37902_Sk | Male | ERalpha-knockout | Skeletal muscle |
SA212521 | 37901_Sk | Male | ERalpha-knockout | Skeletal muscle |
SA212522 | 37898_Sk | Male | ERalpha-knockout | Skeletal muscle |
SA212525 | 37904_Sk | Male | ERalpha-knockout | Skeletal muscle |
SA212506 | 37902_H | Male | ERalpha-knockout | Ventricles |
SA212507 | 37901_H | Male | ERalpha-knockout | Ventricles |
SA212508 | 37904_H | Male | ERalpha-knockout | Ventricles |
SA212509 | 37898_H | Male | ERalpha-knockout | Ventricles |
SA212517 | 37908_H | Male | ERalpha-knockout | Ventricles |
SA212541 | 37894_epi | Male | Floxed Control | EPlasmaididymal fat |
Collection:
Collection ID: | CO002308 |
Collection Summary: | Ventricles were dissected from mice such that each sample will include left and right ventricular tissue.Tissues were snap frozen in liquid nitrogen and stored in -80 freezer until tissues were processed for lipid extractions Blood was collected via cardiac puncture and stored in EDTA tubes on ice. EDTA tubes were spun at 3000g for 15 mins at 4 degrees. Plasma was then collected from these tubes (supernatant) and then stored at -80 degrees. |
Sample Type: | Ventricles, Plasma, Skeletal Muscles, Liver, Epididymal fat |
Storage Conditions: | -80℃ |
Collection Vials: | 1.5ml eppendorf tubes |
Storage Vials: | 1.5ml eppendorf tubes |
Treatment:
Treatment ID: | TR002327 |
Treatment Summary: | Mice did not undergo specific treatment, as this was a basal phenotyping study. Mice were fasted for 6 hours before dissections, and a lethal dose of anesthesia was delivered via intraperitoneal injection before tissue collection. |
Animal Anesthesia: | Pentobarbitone |
Animal Fasting: | 6 hours |
Sample Preparation:
Sampleprep ID: | SP002321 |
Sampleprep Summary: | tissues was homogenised in 1xPBS and then sonicated with a probe-sonicator for 15 seconds, 23 amplitude. BCA assays were then conducted to determine protein concentrations of these homogenates. Lipid extraction was conducted using 10ul of sample (ventricle, skeletal muscle homogenate at 5mg/ml, fat homogenate at 2mg/ml and liver homogenate at 2.5mg/ml) using the single phase chloroform methanol method. 10ul of internal standards and 200ul of chloroform:methanol (1:2) were added to samples before the mixture was vortexed. Samples were then placed on a rotary shaker for 10 mins at a speed of 90 before being transferred to a bath sonicator. Samples were then sonicated for 30 mins at water temperature below 28 degrees. Samples were then removed and rested at room temperature for 20 mins. Samples were then centrifuged at 13000rpm for 10 minutes. 200ul of the supernatant was then transferred to 0.5ml polypropylene 96 well plates, and spun dried using a speedvac vacuum concentrator. Lipids were reconstituted in 50ul water saturated butanol + 50ul of Ammonium Formate. |
Sampleprep Protocol Filename: | Agilent_appnote |
Extract Storage: | -80℃ |
Combined analysis:
Analysis ID | AN003638 |
---|---|
Analysis type | MS |
Chromatography type | Reversed phase |
Chromatography system | Agilent 1290 Infinity II |
Column | Agilent Zorbax Eclipse Plus C18 (100 x 2.1mm, 1.8 um) |
MS Type | ESI |
MS instrument type | Triple quadrupole |
MS instrument name | Agilent 6490 QQQ |
Ion Mode | POSITIVE |
Units | pmol per mg (tissues) pmol per ml (plasma) |
Chromatography:
Chromatography ID: | CH002693 |
Chromatography Summary: | The running solvent consisted of solvent A: 50% H2O / 30% acetonitrile / 20% isopropanol (v/v/v) containing 10mM ammonium formate and 5uM medronic acid, and solvent B: 1% H2O / 9% acetonitrile / 90% isopropanol (v/v/v) containing 10mM ammonium formate. We utilized a stepped linear gradient with a 16-minute cycle time per sample and a 1µL sample injection. To increase throughput, we used a dual column set up to equilibrate the second column while the first is running a sample. The sample analytical gradient was as follows: starting with a flow rate of 0.4mL/minute at 15% B and increasing to 50% B over 2.5 minutes, then to 57% over 0.1 minutes, to 70% over 6.4 minutes, to 93% over 0.1 minute, to 96% over 1.9 minutes and finally to 100% over 0.1 minute. The solvent was then held at 100% B for 0.9 minutes (total 12.0 minutes). Equilibration was started as follows: solvent was decreased from 100% B to 15% B over 0.2 minutes and held until a total of 16 minutes. The next sample is injected and the columns are switched. |
Instrument Name: | Agilent 1290 Infinity II |
Column Name: | Agilent Zorbax Eclipse Plus C18 (100 x 2.1mm, 1.8 um) |
Flow Gradient: | starting with a flow rate of 0.4mL/minute at 15% B and increasing to 50% B over 2.5 minutes, then to 57% over 0.1 minutes, to 70% over 6.4 minutes, to 93% over 0.1 minute, to 96% over 1.9 minutes and finally to 100% over 0.1 minute. The solvent was then held at 100% B for 0.9 minutes (total 12.0 minutes). Equilibration was started as follows: solvent was decreased from 100% B to 15% B over 0.2 minutes and held until a total of 16 minutes. |
Flow Rate: | 0.4mL/min |
Solvent A: | 50% water/30% acetonitrile/20% isopropanol; 10mM ammonium formate; 5uM medronic acid |
Solvent B: | 1% water/9% acetonitrile/90% isopropanol; 10mM ammonium formate |
Chromatography Type: | Reversed phase |
MS:
MS ID: | MS003389 |
Analysis ID: | AN003638 |
Instrument Name: | Agilent 6490 QQQ |
Instrument Type: | Triple quadrupole |
MS Type: | ESI |
MS Comments: | Details previously published in https://doi.org/10.1016/j.chembiol.2018.10.008 Analysis of plasma extracts was performed on an Agilent 6490 QQQ mass spectrometer with an Agilent 1290 series HPLC system and a ZORBAX eclipse plus C18 column (2.1x100mm 1.8μm, Agilent) with the thermostat set at 60°C. Mass spectrometry analysis was performed in positive ion mode with dynamic scheduled multiple reaction monitoring (MRM). Mass spectrometry settings and MRM transitions for each lipid class, subclass and individual species are shown in Tables 1 and S1. The solvent system consisted of solvent A) 50% H2O / 30% acetonitrile / 20% isopropanol (v/v/v) containing 10mM ammonium formate and solvent B) 1% H2O / 9% acetonitrile / 90% isopropanol (v/v/v) containing 10mM ammonium formate. We utilized a stepped linear gradient with a 15-minute cycle time per sample and a 1μL sample injection. The gradient was as follows; starting with a flow rate of 0.4ml/minute at 10% B and increasing to 45% B over 2.7 minutes, then to 53% over 0.1 minutes, to 65% over 6.2 minutes, to 89% over 0.1 minute, to 92% over 1.9 minutes and finally to 100% over 0.1 minute. The solvent was then held at 100% B for 0.8 minutes (total 11.9 minutes). Equilibration was as follows, solvent was decreased from 100% B to 10% B over 0.1 minute and held for an additional 0.9 minutes. Flow rate was then switched to 0.6 ml/minute for 1 minute before returning to 0.4 ml/minute over 0.1 minutes. Solvent B was held at 10% B for a further 0.9 minutes at 0.4ml/minutes for a total cycle time of 15 minutes. The following mass spectrometer conditions were used; gas temperature, 150°C, gas flow rate 17L/min, nebulizer 20psi, Sheath gas temperature 200°C, capillary voltage 3500V and sheath gas flow 10L/min. Isolation widths for Q1 and Q3 were set to “unit” resolution (0.7 amu). PQC samples consisting of a pooled set of 6 healthy individuals were incorporated into the analysis at 1 PQC per 18 plasma samples. TQC consisted of PQC extracts which were pooled and split into individual vials to provide a measure of technical variation from the mass spectrometer only. These were included at a ratio of 1 TQC per 18 plasma samples. TQCs were monitored for changes in peak area, width and retention time to determine the performance of the LC-MS/MS analysis and were subsequently used to align for differential responses across the analytical batches. |
Ion Mode: | POSITIVE |